Fig. 4.

Combined treatment with KCC-07 and DNA damaging reagents shows additive effects on suppression of tumor cell growth. Proliferation analysis following KCC-07 and/or DNA damaging reagent treatment measured by SRB assay. All combined treatments with KCC-07 and DNA damaging reagents show additive reduction of proliferation in U-87MG and SH-SY5Y cell lines. These data suggest the benefit of combined treatments with KCC-07, an epigenetic modifier via MBD2 inhibition, and DNA damaging reagents to treat brain tumors, which can minimize the side effects of DNA damaging reagent regimens. Representative data are shown in the graphs (n=6). Each experiment was repeated twice independently. The experimental conditions of drug treatments are indicated in the figure.